Ocugen (OCGN) EPS (Weighted Average and Diluted) (2017 - 2026)
Ocugen (OCGN) reported EPS (Weighted Average and Diluted) of -$0.06 for Q1 2026, down 20.0% on a YoY basis from -$0.08 in Q1 2025, and down 20.0% quarter-over-quarter from -$0.05 in Q2 2025.
Ocugen (OCGN) EPS (Weighted Average and Diluted) (2017 - 2026) Analysis & Trends
Ocugen has reported EPS (Weighted Average and Diluted) for 10 years, with the latest figure at -$0.06 in Q1 2026.
- For the quarter ending Q1 2026, EPS (Weighted Average and Diluted) fell 20.0% year-over-year to -$0.06; the trailing twelve-month figure through Mar 2026 stood at -$0.11 (up 85.14% YoY), and the FY2024 full-year result was -$0.8, down 209.87% from the prior year.
- EPS (Weighted Average and Diluted) for Q1 2026 stood at -$0.06, down from -$0.05 in the prior quarter.
- The five-year high for EPS (Weighted Average and Diluted) was -$0.04 in Q2 2024, with the low at -$0.65 in Q4 2024.
- Historically, EPS (Weighted Average and Diluted) has averaged -$0.12 across 5 years, with a median of -$0.08 in 2023.
- The largest YoY upside for EPS (Weighted Average and Diluted) was 60.0% in 2024 against a maximum downside of 1347.7% in 2024.
- Ocugen's EPS (Weighted Average and Diluted) stood at -$0.1 in 2022, then soared by 55.1% to -$0.04 in 2023, then tumbled by 1347.7% to -$0.65 in 2024, then soared by 92.31% to -$0.05 in 2025, then slipped by 20.0% to -$0.06 in 2026.
- The last three EPS (Weighted Average and Diluted) figures came in at -$0.06 (Q1 2026), -$0.05 (Q2 2025), and -$0.05 (Q1 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EPS (Weighted Avg. Diluted) (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | 0.68 |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | 3.06 |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | 3,086.42 |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | 0.00 |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | 0.00 |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 4.02 |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | -0.61 |
| 10 | Ocugen | 411.07 Mn | 411.07 Mn | - | -0.06 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -0.06 |
| Jun 30, 2025 | -0.05 |
| Mar 31, 2025 | -0.05 |
| Dec 31, 2024 | -0.65 |
| Jun 30, 2024 | -0.04 |
| Dec 31, 2023 | -0.04 |
| Jun 30, 2023 | -0.10 |
| Mar 31, 2023 | -0.08 |
| Dec 31, 2022 | -0.10 |
| Sep 30, 2022 | -0.11 |
| Jun 30, 2022 | -0.10 |
| Mar 31, 2022 | -0.09 |
| Dec 31, 2021 | -0.07 |
| Sep 30, 2021 | -0.05 |
| Jun 30, 2021 | -0.13 |
| Mar 31, 2021 | -0.04 |
| Dec 31, 2020 | 0.02 |
| Sep 30, 2020 | -0.07 |
| Jun 30, 2020 | -0.19 |
| Dec 31, 2019 | 0.89 |